Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis
NCT02874092Phase 4Completed
- Sponsor
- NYU Langone Health
- Start
- Nov 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor in rheumatoid arthritis (RA) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Disease Activity Score for 28-joint Counts at 30 days. Started Nov 2016; status: completed.
02
Drugs
ticagrelor
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02874092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874092.